• BRIAKINUMAB chembl:CHEMBL1742995 Immunotherapy

    Alternate Names:

    OZESPA
    J695
    BSF-415977
    BRIAKINUMAB
    A-796874.0
    ABT-874
    J-695
    LU-415977
    WAY-165772

    Drug Info:

    FDA Approval not approved
    Drug Class monoclonal antibody
    Drug Indications antiinflammatory agent,for treatment of multiple sclerosis,antipsoriatic
    (0 More Sources)

    Publications:

  • Interaction Score: 12.37

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Briakinumab
    Novel drug target Established target
    Mechanism of Interaction Interleukin-23 inhibitor

    PMIDs:
    None found


  • Interaction Score: 10.3

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name Briakinumab
    Mechanism of Interaction Interleukin-12 inhibitor

    PMIDs:
    None found


  • Interaction Score: 6.87

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Briakinumab
    Novel drug target Established target
    Mechanism of Interaction Interleukin-23 inhibitor

    PMIDs:
    None found


    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antiinflammatory agent,for treatment of multiple sclerosis,antipsoriatic
    Drug Class monoclonal antibody
    FDA Approval not approved

    Publications:

    • Version: 2020.06.01

    Alternate Names:
    D0H1TL TTD Drug ID

    Drug Info:

    Publications:

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications: